IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Avi ORR-URTREGER et al

Serial No.:

10/516,303

Filed:

10-Dec-2004

For:

METHOD OF DETECTING AND TREATING

PROSTATE CANCER

Examiner:

HALVORSON, MARK

\$ \$ \$ \$ \$ \$ \$



Group Art Unit: 1642

Attorney

Docket: 28906

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: November 12, 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMER

JAHA VIEP	aperwork	Keduction Act of 1995, no persons	are required t	o respond to a	collection of information unless it contains	a valid Of lete if K		
		Substitute for form 1449A/	PTO		Application Number		16,303	
1	INFO	RMATION DISC	TOST	P E		ı	ember 10, 2004	
_					Filing Date			
i	SIA	TEMENT BY API	LICA	NI	First Named Inventor	Avi	ORR-URTREGER et al	
	(1	ise as many sheets as ned	cessary)		Art Unit 1642		2	
					Examiner Name	HAI	HALVORSON, MARK	
Sheet		1	of	7	Attorney Docket Number	2890	06	
			IIS	PATENT	DOCUMENTS	ш.		
Examiner	Cite	Document Number	Public	ation Date	Name of Patentee or		Pages, Columns, Lines, Where	
Initials*	No. 1		MM-I	D-YYYY	Applicant of Cited Document		Relevant Passages or Relevan Figures Appear	
		Number-Kind Code ^{2 (if known)}			1		rigures Appear	
	1	US-4,476,301	10-09-1		Imbach et al.			
	2	US-4,656,127	04-07-1		Mundy	-		
	3	US-4,666,828	05-19-1	987	Gusella			
	4	US-4,683,202	07-28-1		Mullis			
	5	US-4,801,531	01-31-1	989	Frossard			
	6	US-4,816,567	03-28-1	989	Cabilliy et al.			
	7	US-4,946,778	08-07-1	990	Ladner et al.			
	8	US-5,011,771	04-30-1	991	Bellet et al.			
	9	US-5,013,830	05-07-1	991	Ohtsuka et al.			
_	10	US-5,023,243	06-11-1	991	Tullis			
	11	US-5,034,506	07-23-1	991	Summerton et al.			
	12	US-5,149,797	09-22-1	992	Pederson et al.			
	13	US-5,166,315	11-24-1	992	Summerton et al.			
	14	US-5,177,196	01-05-1	993	Meyer, Jr. et al.			
	15	US-5,185,444	02-09-1	993	Summerton et al.			
	16	US-5,188,897	02-23-1	993	Suhadolnik et al.			
	17	US-5,192,659	03-09-1	993	Simons			
	18	US-5,214,134	05-25-1		Weis et al.			
	19	US-5,216,141	06-01-1		Benner			
	20	US-5,220,007	01-15-1		Pederson et al.			
	21	US-5,235,033	08-10-1		Summerton et al.			
	22	US-5,256,775	10-26-1		Froehler			
	23	US-5,264,423	01-23-1		Cohen et al.			
	24	US-5,264,562	11-23-1		Matteucci et al.			
	25	US-5,264,564	11-23-1		Matteucci et al.			
	26	US-5,272,057	12-21-1		Smulson et al.			
	27	US-5,276,019	01-04-1		Cohen et al.			
	28	US-5,278,302	01-11-1		Caruthers et al.			
	29	US-5,286,717	02-15-1		Cohen et al.			
	30	US-5,321,131	06-14-1		Agrawal et al.			
	31	US-5,366,878	11-22-1		Pederson et al.			
	32	US-5,399,676	03-21-1		Froehler			
	+	7:0 5 100 511	1 24 24 1	1005	337 11 4 1		† · · · · · · · · · · · · · · · · · · ·	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Walder et al.

04-04-1995

33

US-5,403,711

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Substitute for form 1449	A/PTO		Application Number	10/516,303	
,		RMATION DIS	CI OSIII) F	••	December 10, 2004	
-					Filing Date		
	STAI	TEMENT BY A	PLICA	N 1	First Named Inventor	Avi ORR-URTREGER et al	
	(1	ise as many sheets as n	ecessary)		Art Unit	1642	
					Examiner Name	HALVORSON, MARK	
Sheet	2		of	7	Attorney Docket Number	28906	
	34	US-5,405,938	04-11-1	995	Summerton et al.		
	35	US-5,405,939	04-11-1		Suhadolnik et al.		
	36	US-5,434,257	07-18-1		Matteucci et al.		
	37	US-5,453,496	09-26-1		Caruthers et al.		
	38	US-5,455,233	10-03-1	· · · · · · · · · · · · · · · · · · ·	Spielvogel et al.		
	39 US-5,466,677 40 US-5,470,967 41 US-5,476,925		11-14-1		Baxter et al.		
			11-28-1		Huie et al.		
			12-19-1		Letsinger et al.		
	42	US-5,489,677	02-06-1		Sanghvi et al.		
	43	US-5,491,133	02-13-1		Walder et al.		
	44	US-5,519,126	05-21-1		Hecht		
	45	US-5,536,821	07-16-1		Agrawal et al.		
	46	US-5,539,082	07-23-1		Nielsen et al.		
	47	US-5,541,306	07-30-1		Agrawal et al.		
	48	US-5,541,307	07-30-1		Cook et al.		
	49	US-5,545,806	08-13-1		Lonberg et al.		
	50	US-5,545,807	08-13-1		Surani et al.		
	51	US-5,550,111	08-27-1		Suhadolnik et al.		
	52	US-5,561,225	10-01-1		Maddry et al.		
	53	US-5,563,253	10-08-1		Agrawal et al.		
	54	US-5,565,350	10-15-1		Kmiec et al.		
	55	US-5,569,825	10-29-1		Lonberg et al.		
	56	US-5,571,799	11-05-1		Tkachuk et al.		
	57	US-5,587,361	06-24-1		Cook et al.		
	58	US-5,589,136	12-31-1		Northrup et al.		
	59	US-5,596,086	01-21-1		Matteucci et al.		
	60	US-5,602,240	02-01-1		De Mesmacker et al.		
	61	US-5,608,046	03-04-1		Cook et al.		
	62	US-5,610,289	03-11-1		Cook et al.		
	63	US-5,618,704	04-08-1		Sanghvi et al		
•	64	US-5,623,065	04-22-1		Cook		
	65	US-5,625,050	04-29-1		Beaton et al.		
	66	US-5,625,126	04-29-1		Lonberg et al.		
	67	US-5,633,360	05-27-1		Bischofberger et al.		
	68	US-5,633,425	05-27-1		Lonberg et al.		
	69	US-5,652,355	07-29-1		Metelev et al.		
	70	US-5,652,356	07-29-1		Agrawal		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Onger the Pa	aperwork	Reduction Act of 1995, no person		will to a CO	T T T T T T T T T T T T T T T T T T T		olete if K		
		Substitute for form 1449A	VPTO		Applica	tion Number	10/51		-
_		RMATION DISC				iling Date December 10, 2004 irst Named Inventor Avi ORR-URTREGE			
;	STAT	TEMENT BY AP	PLICANT		First Na			ORR-URTREGER et al	
	(u	ise as many sheets as ne	cessary)		Art Unit 16		1642	Alexander	
					Examin	er Name	HAL	VORSON, MARK	
Sheet		3	of 7		Attorne	y Docket Number	28906		
	71	US-5,661,016	08-26-1997		1	Lonberg et al.			
	72	US-5,663,312	09-02-1977			Chaturvedula			
	73	73 US-5,677,437 10-14-197				Teng et al.			
	74					Weis et al.			
-			12-23-1997			Cook			
	76			02-03-1998		Buchardt et al.			
	. 77	US-5,719,262 02-17			Buchardt et al.				
	78					Yayon et al.			
	79	US-6,303,374	10-16-2001		Zhang et al.				
	80	US-6,326,174	12-04-2001	12-04-2001 Joyce et al. 12-18-2001 Silverman det al.					
	81	US-6,331,396	12-18-2001			Silverman det al.			
	82	US-2002/0108142	08-02-2002)2 K		Kapranov et al.			
	83	US-2002/0086356	07-04-2002			Tuschl et al.			
	84	US-5,623, 070	04-22-1997	04-22-1997		Cook et al.			
	85	US-3,687,808	08-29-1972			Merigan, Jr. et al.			
	86	US-4,036,945	07-19-1977		Haber				
	87	US-4,331,647	05-25-1982	2 Goldenberg					
	88	US-4,469,863	09-04-1984		Ts'o et al.				
			FOREIG	N PATE	ENT DOC	CUMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Doc			ation Date	Name of Patentee Applicant of Cited Do		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	ļ.,	Country Code ³ Number ⁴ Kind	Code ⁵ (if known)	22.1	1000			or Relevant Figures Appear	
	89	PCT WO 92/15712		09-17-	1992	Goellet et al			
	90	PCT WO 03/000112		01-3-2	003	Carpten et al.			
Examine	ــــــــــــــــــــــــــــــــــــــ	101 110 05/000112				Date			
Signatur	-					Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Trainstation is attactive.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		the Paperwork Reduction Act of 1995, no persons are re	44		te if Known	Towns control name
	Sub	ostitute for form 1449A/PTO		Application Number	10/516,303	
,	INEAD	MATION DISCLOSURE		Filing Date	December 10, 2004	
1				First Named Inventor		TREGER et al
;	STATE	MENT BY APPLICANT		Group Art Unit	1642	
	(as many sheets as necessary)		Examiner Name	HALVORSO	N, MARK
	` `					
Sheet	4	Of	7	Attorney Docket Number	28906	
		OTHER PRIOR ART – NON I				
Examiner	Cite	Include name of the author (in CAPITAL LE item (book, magazine, journal, serial sympos				_2
Initials	No.1			ry where published.	ue number(s),	T ²
	91	Fingl et al. "Goodman & Gilman's: Th			eutics".	
		McGraw-Hill Professional, Chap.1, P			,	
	92	Marks et al. By-Passing Immunization			ntibodies by	
	-	Chain Shuffling", Biotechnology 10:			,	
	93	Brummelkamp et al. "A System for St			g RNAs in	
		Mammalian Cells", Science, 296: 550				
	94	Miyagishi et al. "U6 Promoter-Driven			rhangs	
		Efficiently Suppress Targeted Gene E				
		Biotechnology, 19: 497-500, 2002;	•	•		
	95	Nyren et al. "Solid Phase DNA Minis	equencir	g by an Enzymatic Lumino	ometric	-17
		Inorganic Pyrophosphate Detection E	ssay", A	nalytic Biochemistry, Vol.2	208, p.171-	
-		175, 1993.	•		-	
	96	Harlow et al. "Antibodies", A Laborat	ory Mar	uel, Cold Spring Harbor, P	2.141-155,	
	,	1988.	•			
	97	Rennert et al. "A Novel Founder Muta	tion in t	he RNASEL Gene, 471del.	AAAG, Is	
		Associated With Prostate Cancer in A	shkenaz	i Jews", American Journal	of Human	
		Genetics, 71: 981-984, 2002.				
	98	Salehzada et al. "Polyclonal Antibodi				
		This Enzyme in Mouse Cells", The Jo	urnal of	Biological Chemistry, 266	(9): 5808-	
		5813, 1991.				
	99	Rökman et al. "Germline Alterations				
	1	at 1q25, in Patients and Families With	Prostate	e Cancer", Am. J. Hum. Ge	net., 70:	
		1299-1304, 2002.			T T	
	100	Jones et al. "Replacing the Compleme			Human	
	101	Antibody With Those From A Mouse	, Nature	5, 321: 322-323,1980.	D LVIV	
	101	Mishell et al. "Selected Methods in Co	enuiar Ir	mmunology, Freeman & C	o., r. 1-XIV,	-
P 80 F 50 F 50	102	1980. Inbar et al. "Localization of Antibody	Combin	sing Sites Within the Variet	ale Portions	
	102	of Heavy and Light Chains", Proc. Na				
	103	Larrick et al. "PCR Amplification of A				2 811
	103	Methods in Enzymology, 2(2): 106-1			pamon to	
	104	Nickerson et al. "Automated DNA Di	agnostic	s Using An ELISA-Based		
	'''	Oligonucleotide Ligation Assay", Pro			3927, 1990.	
	105	Bird et al. "Single-Chain Antigen-Bin				
	1.33	1988.		· · · · · · · · · · · · · · · · · · ·	 ,	
		January				,,,,

Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.① . Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/516,303 Filing Date December 10, 2004 INFORMATION DISCLOSURE First Named Inventor Avi ORR-URTREGER et al STATEMENT BY APPLICANT Group Art Unit HALVORSON, MARK **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 5 Of 7 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Breaker et al. "A DNA Enzyme With Mg2+-Dependent RNA Phosphoesterase 106 Activity", Chemistry & Biology, 2: 655-660, 1995. Khachigian "DNAzymes: Cutting A Path to A New Class of Therapeutics", Current 107 Opinion in Molecular Therapeutics, 4(2): 119-121, 2002. Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole 108 Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli", Bio/Technology, 11: 1271-1277, 1993. Santoro et al. "A General Purpose RNA-Cleaving DNA Enzyme", Proc. Natl. Acad. 109 Sci. USA, 94: 4262-4266, 1997. 110 Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368: 856-859, 1994. Neuberger "Generating High-Avidity Human Mabs in Mice", Nature Biotechnology, 111 Fishwild et al. "High-Avidity Human IgGk Monoclonal Antibodies From A Novel 112 Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996. Morrison "Success in Specification", Nature, 368(6474): 812-813, 1994. 113 Boerner et al. "Production of Antigen-Specific Human Monoclonal Antibodies From 114 In Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, Lonberg et al. "Human Antibodies From Transgenic Mice", International Review in 115 Immunology, 13: 65-93, 1995. Hutvágner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in 116 Genetics & Development, 12: 225-232, 2002. 117 Berry et al. "Evidence for A Prostate Cancer-Susceptibility Locus on Chromosome 20", American Journal of Human Genetics, 67: 82-91, 2000. Berthon et al. "Predisposing Gene for Early-Onset Prostate Cancer, Localized on 118 Chromosome 1q42.2-43", American Journal of Human Genetics, 62(6): 1416-1424, 1998. Abstract. Bisbal et al. "Cloning and Characterization of A Rnase L Inhibitor", The Journal of 119 Biological Chemistry, 270(22): 13308-13317, 1995. Carter et al. "Mendelian Inheritance of Familial Prostate Cancer", Proc. Natl. Acad. 120 Sci. USA, 89: 3367-3371, 1992. Englisch et al. "Chemically Modified Oligonucleotides as Probes and Inhibitors", 121 Angewandte Chemie, International Edition, 30(6): 613-629, 1991. Abstract.

		<u>.</u> .
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Olidei	the Paperwork Reduction Act of 1993, no persons are required to te						
	Sul	bstitute for form 1449A/PTO	Complete if Known Application Number 10/516,303					
Ì	DECE	MARION DIGGLOGUDE	Filing Date	December 10, 2004				
	INFOR	MATION DISCLOSURE	First Named Inventor	Avi ORR-URTREGER et al				
	STATE	EMENT BY APPLICANT	Group Art Unit	1642				
			Examiner Name	HALVORSON, MARK				
	(use	as many sheets as necessary)						
Sheet	6	Of 7	Attorney Docket Number	28906				
		OTHER PRIOR ART – NON PATEN						
	122	Hacia et al. "Detection of Heterozygous Mu						
		Oligonucleotide Arrays and Two-Colour Flu		e Genetics,				
		14(4): 441-447, 19						
	123	Haff et al. "Multiplex Genotyping of PCF						
		Primers", Nucleic Acids Research						
	124	Harju et al. "Colorimetric Solid-Phase Minise						
		of Alpha 1-Antitrypsin Z Mutation", Clinical	Chemistry, 39(11/Pt.1): 228	32-2287,				
		1993. Abstract.						
	125	Hassel et al. "A Dominant Negative Mutant of						
		Antiproliferative and Antiviral Effects of Interferon", The EMBO Journal, 12(8):						
	3297-3304, 1993.							
	126 Hubert et al. "The Jewish Ashkenazi Founder Mutations in the BRCA1/BRCA2							
	Genes Are Not Found at An Increased Frequency in Ashkenazi Patients With							
		Prostate Cancer", American Journal of Human	Genetics, 65: 921-924, 19	99.				
	127	Kozal et al. "Extensive Polymorphisms Obser	ved in HIV-1 Clade B Prote	ease Gene				
		Using High-Density Oligonucleotide Arrays",	Nature Medicine, 2(7): 753	3-759, 1996.				
		Abstract.						
	128	Laken et al. "Familial Colorectal Cancer in As	shkenazim Due to A Hyperi	mutable				
		Tract in APC", Nature Genetics, 17(1): 79-83	, 1997. Abstract.					
	129	Landegren et al. "Reading Bits of Genetic Info		le-				
		Nucleotide Polymorphism Analysis", Genome						
	130	Lengyel "Tumor-Suppressor Genes: News Ab						
		Natl. Acad. Sci. USA, 90: 5893-5895, 1993.						
	131	Lichtenstein et al. "Environmental and Herital	ole Factors in the Causation	of Cancer-				
		Analyses of Cohorts of Twins From Sweden,						
		Journal of Medicine, 343(2): 78-85, 2000. Ab		-				
	132	Livak et al. "A Microtiter Plate Assay for Det	ermining Apolipoprotein E	Genotype				
		and Discovery of A Rare Allele", Human Mut						
	133	Orita et al. "Detection of Polymorphisms of H						
:		Single-Strand Conformation Polymorphisms"						
		2770, 1989.	,					
	1	1	<u></u>					

Considered Signature

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form. call 1-800-PTO-9199 and select ontion 2

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number.

		the Paperwork Reduction Act of 1995, no persons are re-	quired to res	pond to a collection of information un Comple	te if Known	MB control numb		
	Sut	ostitute for form 1449A/PTO		Application Number	10/516,303			
	INFOR	MATION DISCLOSURE		Filing Date	December 10, 200)4		
				First Named Inventor	Avi ORR-URTR	EGER et al		
	STATE	MENT BY APPLICANT		Group Art Unit	1642			
	(use	as many sheets as necessary)		Examiner Name	HALVORSON, N	/ARK		
Sheet	7	Of	7	Attorney Docket Number	28906			
		OTHER PRIOR ART – NON I						
	134	Parker et al. "Cancer Statistics, 1996", 5-27, 1996.						
	135	Pastinen et al. "Minisequencing: A Sp on Oligonucleotide Arrays", Genome			Diagnostics			
	136	Porter "The Hydrolysis of Rabbit γ-G Papain", Biochemical Journal, 73: 119	lobulin a	nd Antibodies With Crysta	Illine			
	137	Shoemaker et al. "Quantitative Phenor	tvnic An	alysis of Yeast Deletion M	utants Using	-		
	13,	A Highly Parallel Molecular Bar-Cod 1996. Abstract.	ing Strat	egy", Nature Genetics, 14(4): 450-456,			
	138	Silverman "Implications for Rnase L i 42(7): 1805-1812, 2003. Abstract.	in Prosta	te Cancer Biology", Bioch	emistry,			
	139	Smith et al. "Major Susceptibility Loc Suggested by A Genome-Wide Search Abstract.						
•	140	Sosnowski et al. "Rapid Determination Hybrids by Direct Electric Field Control 1123, 1997.						
	141	Squire et al. "Localization of the Inter (RNS4) to Human Chromosome 1q25				_		
	142	Steinberg et al. "Family History and the 337-347, 1990. Abstract.	he Risk o	of Prostate Cancer", Prosta	te, 17(4):	•		
-	143	Struewing et al. "The Carrier Frequen	quency of the BRCA1 185delAG Mutation Is tenazi Jewish Individuals", Nature Genetics, 11(2):					
<u> </u>	144	Syvanen "Detection of Point Mutation Minisequencing Method", Clinica Chi			nation", Nature			
	145	Tavtigian et al. "A Candidate Prostate 17p", Nature Genetics, 27: 172-180, 2	Cancer					
	146	Tyagi et al. "Multicolor Molecular Be Biotechnology, 16: 49-53, 1998. Abst	acons fo	r Allele Discrimination", N				
	147	Verhoeyen et al. "Reshaping Human Activity", Science, 239(4847): 1534-1	Antibodi 1536, 19	88. Abstract.				
	148							
	149	Zhou et al. "Expression Cloning of 2- Mediator of Interferon Action", Cell,			Regulated			
	150	Hoogenboom et al. "By-Passing Imme Repertoires of Germline VH Gene Se Molecular Biology, 227(2): 381-388,	unisation gments I	n. Human Antibodies From Rearranged In Vitro", Journ				

Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount